Mark A. Behlke

16.8k total citations · 4 hit papers
139 papers, 11.1k citations indexed

About

Mark A. Behlke is a scholar working on Molecular Biology, Immunology and Cancer Research. According to data from OpenAlex, Mark A. Behlke has authored 139 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Molecular Biology, 33 papers in Immunology and 31 papers in Cancer Research. Recurrent topics in Mark A. Behlke's work include RNA Interference and Gene Delivery (63 papers), Advanced biosensing and bioanalysis techniques (48 papers) and MicroRNA in disease regulation (28 papers). Mark A. Behlke is often cited by papers focused on RNA Interference and Gene Delivery (63 papers), Advanced biosensing and bioanalysis techniques (48 papers) and MicroRNA in disease regulation (28 papers). Mark A. Behlke collaborates with scholars based in United States, Australia and United Kingdom. Mark A. Behlke's co-authors include Kim A. Lennox, Dennis Y. Loh, Richard Owczarzy, Ashley M. Jacobi, Joseph A. Walder, Garrett R. Rettig, Hubert S. Chou, Yong You, Andrew Tsourkas and Christopher A. Vakulskas and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Mark A. Behlke

137 papers receiving 10.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of preexisting adaptive immunity to Cas9 proteins in humans

2019 665 citations Carsten T. Charlesworth, Daniel P. Dever et al. Nature Medicine profile →
Progress towards in Vivo Use of siRNAs

2006 547 citations Mark A. Behlke Molecular Therapy profile →
A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells

2018 541 citations Christopher A. Vakulskas, Daniel P. Dever et al. Nature Medicine profile →
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy

2020 430 citations Daniel Rosenblum, Anna Gutkin et al. Science Advances profile →

Peers

Countries citing papers authored by Mark A. Behlke

Since Specialization

Citations

This map shows the geographic impact of Mark A. Behlke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Behlke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Behlke more than expected).

Fields of papers citing papers by Mark A. Behlke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Behlke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Behlke. The network helps show where Mark A. Behlke may publish in the future.

Co-authorship network of co-authors of Mark A. Behlke

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Behlke. A scholar is included among the top collaborators of Mark A. Behlke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Behlke. Mark A. Behlke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CRISPAltRations: A validated cloud-based approach for interrogation of double-strand break repair mediated by CRISPR genome editing 2021 ·Molecular Therapy — Methods & Clinical Development ·Gavin Kurgan, Rolf Turk, Heng Li, (unknown), Garrett R. Rettig, Ashley M. Jacobi, (unknown), Morgan Sturgeon, (unknown), (unknown), (unknown), Mark A. Behlke, Yu Wang, Matthew McNeill	13
2	Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′-O-methyl gapmer oligonucleotides 2021 ·Nucleic Acids Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Kim A. Lennox, Julia I. Ellyard, (unknown), Tomalika R. Ullah, Gina D. Kusuma, Geneviève Pépin, Hongmei Li, Jaclyn S. Pearson, Jonathan Ferrand, Rebecca Lim, Rakesh N. Veedu, Eric F. Morand, Carola G. Vinuesa, Mark A. Behlke, Michael P. Gantier	17
3	High-Level Correction of the Sickle Mutation is Amplified in Vivo During Erythroid Differentiation 2021 ·SSRN Electronic Journal ·Wendy Magis, Mark A. DeWitt, Stacia K. Wyman, Jonathan T. Vu, Seok‐Jin Heo, Shirley Shao, (unknown), Zulema Romero, Beatriz Campo Fernandez, Suzanne Saïd, Matthew McNeill, Garrett R. Rettig, Yongming Sun, Yu Wang, Mark A. Behlke, (unknown), Dario Boffelli, Mark C. Walters, Jacob E. Corn, David I. K. Martin	1
4	Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists 2020 ·Nucleic Acids Research ·(unknown), (unknown), Kim A. Lennox, (unknown), (unknown), (unknown), (unknown), Geneviève Pépin, (unknown), Marcel F. Nold, Claudia A. Nold‐Petry, Mark A. Behlke, Michael P. Gantier	24
5	CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy breakdown → 2020 ·Science Advances ·Daniel Rosenblum, Anna Gutkin, Ranit Kedmi, Srinivas Ramishetti, Nuphar Veiga, Ashley M. Jacobi, Mollie S. Schubert, Dinorah Friedmann‐Morvinski, Zvi R. Cohen, Mark A. Behlke, Judy Lieberman, Dan Peer	430
6	Systematic in vitro profiling of off-target affinity, cleavage and efficiency for CRISPR enzymes 2020 ·Nucleic Acids Research ·Liyang Zhang, H. Tomas Rube, Christopher A. Vakulskas, Mark A. Behlke, Harmen J. Bussemaker, Miles A. Pufall	31
7	Identification of preexisting adaptive immunity to Cas9 proteins in humans breakdown → 2019 ·Nature Medicine ·Carsten T. Charlesworth, (unknown), Daniel P. Dever, Joab Camarena, Viktor T. Lemgart, M. Kyle Cromer, Christopher A. Vakulskas, Michael A. Collingwood, Liyang Zhang, Nicole M. Bode, Mark A. Behlke, Beruh Dejene, Brandon Cieniewicz, Rosa Romano, Benjamin J. Lesch, Natalia Gomez‐Ospina, Sruthi Mantri, Mara Pavel-Dinu, Kenneth I. Weinberg, Matthew H. Porteus	665
8	Engineered transfer RNAs for suppression of premature termination codons 2019 ·Nature Communications ·John D. Lueck, Jae Seok Yoon, Alfredo Perales‐Puchalt, (unknown), Daniel T. Infield, Mark A. Behlke, (unknown), David B. Weiner, William R. Skach, Paul B. McCray, Christopher A. Ahern	105
9	Evaluation and Reduction of CRISPR Off-Target Cleavage Events 2019 ·Nucleic Acid Therapeutics ·Christopher A. Vakulskas, Mark A. Behlke	85
10	A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells breakdown → 2018 ·Nature Medicine ·Christopher A. Vakulskas, Daniel P. Dever, Garrett R. Rettig, Rolf Turk, Ashley M. Jacobi, Michael A. Collingwood, Nicole M. Bode, Matthew McNeill, Shuqi Yan, Joab Camarena, Ciaran M. Lee, So Hyun Park, Volker Wiebking, Rasmus O. Bak, Natalia Gomez‐Ospina, Mara Pavel-Dinu, Wenchao Sun, Gang Bao, Matthew H. Porteus, Mark A. Behlke	541
11	Preclinical Development of HBB Gene Correction in Autologous Hematopoietic Stem and Progenitor Cells to Treat Severe Sickle Cell Disease 2017 ·Blood ·Daniel P. Dever, Joab Camarena, Ciaran M. Lee, Christopher A. Vakulskas, Mark A. Behlke, Gang Bao, Matthew H. Porteus	4
12	Cre-dependent DNA recombination activates a STING-dependent innate immune response 2016 ·Nucleic Acids Research ·Geneviève Pépin, Jonathan Ferrand, Klara Höning, W. Samantha N. Jayasekara, Jason E. Cain, Mark A. Behlke, Daniel J. Gough, Bryan R.G. Williams, Veit Hornung, Michael P. Gantier	35
13	Symposium Session Summaries 2013 ·Pediatric Pulmonology ·Shyam Ramachandran, Philip H. Karp, (unknown), Mark A. Behlke, Michael J. Welsh, Paul B. McCray, Daniela Rotin, (unknown), Dana Carroll, Mitchell L. Drumm, (unknown), (unknown), Ilya Bederman, Jean Eastman, Aura Perez, Craig A. Hodges, Jeffrey M. Beekman, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
14	Post-Transcriptional Regulation of Cystic Fibrosis Transmembrane Conductance Regulator Expression and Function by MicroRNAs 2013 ·American Journal of Respiratory Cell and Molecular Biology ·Shyam Ramachandran, Philip H. Karp, (unknown), Peng Jiang, Christine Wohlford-Lenane, Kim A. Lennox, Ashley M. Jacobi, (unknown), Scott D. Rose, Mark A. Behlke, Yi Xing, Michael J. Welsh, Paul B. McCray	84
15	Alternative RISC assembly: Binding and repression of microRNA–mRNA duplexes by human Ago proteins 2012 ·RNA ·Maja M. Janas, Bingbing Wang, (unknown), Mike Aguiar, Jonathan M. Shaffer, (unknown), Mark A. Behlke, Kai W. Wucherpfennig, Steven P. Gygi, Étienne Gagnon, Carl D. Novina	99
16	Progress Toward In Vivo Use of siRNAs-II 2011 ·Molecular Therapy ·Garrett R. Rettig, Mark A. Behlke	175
17	Determinants of Cytokine Induction by Small Interfering RNA in Human Peripheral Blood Mononuclear Cells 2008 ·Journal of Interferon & Cytokine Research ·Maryam Zamanian-Daryoush, João T. Marques, Michael P. Gantier, Mark A. Behlke, Matthias John, Patricia Rayman, James H. Finke, Bryan Williams	47
18	Designing and Utilization of siRNAs Targeting RNA Binding Proteins 2008 ·Methods in molecular biology ·Dongho Kim, Mark A. Behlke, John J. Rossi	1
19	Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction 2005 ·Virology ·Murali Ramaswamy, Lei Shi, Steven M. Varga, Sailen Barik, Mark A. Behlke, Dwight C. Look	138
20	Expression of a murine polyclonal T cell receptor marker correlates with the use of specific members of the V beta 8 gene segment subfamily. 1987 ·The Journal of Experimental Medicine ·Mark A. Behlke, Tim Henkel, Sarah Anderson, N C Lan, Leroy Hood, V L Braciale, T J Braciale, Dennis Y. Loh	70

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact